James Bluett

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 23

Top Venues

Rheumatology advances in practice

The British journal of dermatology

Neuropsychiatric disease and treatment

Open access rheumatology : research and reviews

University of Manchester (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Manchester

United Kingdom

PHD

University of Manchester

United Kingdom

MSC

Publications

Philippa D K Curry, Andrew P Morris, Meghna Jani, Gabriela Arredondo Hector Chinoy, Richard B Warren, James Bluett, null null
Psoriatic arthritis: the role of self-reported non-adherence, non-trough drug levels, immunogenicity and conventional synthetic DMARD co-therapy in adalimumab and etanercept response. Rheumatology advances in practice 8 (1) (2024)
Stephanie F Ling, Kayode Ogungbenro, Adam S Darwich, Amirah Binti Mohammad Ariff, Nisha Nair, James Bluett, Ann W Morgan, John D Isaacs, Anthony G Wilson, Kimme L Hyrich, Richard B Warren, Darren Plant
Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis. Pharmaceutics 16 (6) (2024)
Stephanie F Ling, Kayode Ogungbenro, Adam S Darwich, Amirah Binti Mohammad Ariff, Nisha Nair, James Bluett, Ann W Morgan, John D Isaacs, Anthony G Wilson, Kimme L Hyrich, Richard B Warren, Darren Plant
Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis. Pharmaceutics 16 (6) (2024)
Max Lyon, Sizheng Steven Zhao, Meghna Jani, Gabriela Arredondo Hector Chinoy, Richard B Warren, James Bluett, null null
The influence of deprivation in the outcomes of psoriatic arthritis within the UK-utilizing Outcomes of Treatment in Psoriatic Arthritis Study Syndicate (OUTPASS) data. Rheumatology advances in practice 8 (2) (2024)
Max Lyon, Sizheng Steven Zhao, Meghna Jani, Gabriela Arredondo Hector Chinoy, Richard B Warren, James Bluett, null null
The influence of deprivation in the outcomes of psoriatic arthritis within the UK-utilizing Outcomes of Treatment in Psoriatic Arthritis Study Syndicate (OUTPASS) data. Rheumatology advances in practice 8 (2) (2024)
Max Lyon, Sizheng Steven Zhao, Meghna Jani, Gabriela Arredondo Hector Chinoy, Richard B Warren, James Bluett, null null
The influence of deprivation in the outcomes of psoriatic arthritis within the UK-utilizing Outcomes of Treatment in Psoriatic Arthritis Study Syndicate (OUTPASS) data. Rheumatology advances in practice 8 (2) (2024)
Seema D Sharma, James Bluett
Towards Personalized Medicine in Rheumatoid Arthritis. Open access rheumatology : research and reviews 16 (2024)
Amelle Geurim Ra, Zoe Littlewood, Richard B Warren, Brian Keevil, Malcolm McTaggart, Richard Bruce Warren, James Bluett
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis. The British journal of dermatology 190 (6) (2024)
Amelle Geurim Ra, Zoe Littlewood, Richard B Warren, Brian Keevil, Malcolm McTaggart, Richard Bruce Warren, James Bluett
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis. The British journal of dermatology 190 (6) (2024)
Amelle Geurim Ra, Zoe Littlewood, Richard B Warren, Brian Keevil, Malcolm McTaggart, Richard Bruce Warren, James Bluett
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis. The British journal of dermatology 190 (6) (2024)
Arav Dagli, Rebecca R Lee, James Bluett
The Effect of Depression on Disease Activity and Treatment Response in Patients with Inflammatory Arthritis: Results from a Narrative Literature Review. Neuropsychiatric disease and treatment 20 (2024)
Arav Dagli, Rebecca R Lee, James Bluett
The Effect of Depression on Disease Activity and Treatment Response in Patients with Inflammatory Arthritis: Results from a Narrative Literature Review. Neuropsychiatric disease and treatment 20 (2024)
Amelle G Ra, Zoe Littlewood, Richard B Warren, Brian Keevil, Malcolm McTaggart, Richard Bruce Warren, James Bluett
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis. The British journal of dermatology (2024)
Philippa D K Curry, Andrew P Morris, Meghna Jani, Gabriela Arredondo Hector Chinoy, Richard B Warren, James Bluett, null null
Psoriatic arthritis: the role of self-reported non-adherence, non-trough drug levels, immunogenicity and conventional synthetic DMARD co-therapy in adalimumab and etanercept response. Rheumatology advances in practice 8 (1) (2024)
Seema D Sharma, James Bluett
Towards Personalized Medicine in Rheumatoid Arthritis. Open access rheumatology : research and reviews 16 (2024)
Philippa D K Curry, Gabriela Arredondo Hector Chinoy, Meghna Jani, Darren Plant, Kimmie L Hyrich, Ann W Morgan, Anthony G Wilson, John Dudley Isaacs, Andrew P Morris, Richard B Warren, James Bluett
The Effect of COVID-19 on Medication Adherence in a Rheumatoid Arthritis (BRAGGSS) and Psoriatic Arthritis (OUTPASS) UK Cohort. The Journal of rheumatology (2023)
Philippa D K Curry, Ryan M Hum, Andrew P Morris, Meghna Jani, Hector Chinoy, Anne Barton, James Bluett, null null
Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis. Rheumatology (Oxford, England) (2023)
Stephanie Church, Kimme L Hyrich, Kayode Ogungbenro, Richard D Unwin, Anne Barton, James Bluett
Development of a sensitive biochemical assay for the detection of tofacitinib adherence. Analytical methods : advancing methods and applications (2023)
Philippa D K Curry, Andrew P Morris, Richard B Warren, James Bluett
Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis? The pharmacogenomics journal (2022)
Syed Sa Gilani, Nisha Nair, Darren Plant, Kimmie L Hyrich, Ann W Morgan, Andrew P Morris, Anthony G Wilson, John Dudley Isaacs, Richard B Warren, James Bluett, null null
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. Pharmacogenomics 21 (16) (2020)
Stephanie F Ling, James Bluett
Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update. Pharmacogenomics 21 (1) (2020)
Sean P Gavan, Meghna Jani, James Bluett, Katherine Payne, Richard B Warren
Therapeutic monitoring of TNF inhibitors for rheumatoid arthritis: evidence required following NICE's recommendations. Rheumatology advances in practice 4 (2) (2020)
James Bluett, Isabel Riba-Garcia, Suzanne M M Verstappen, Thierry Wendling, Kayode Ogungbenro, Richard D Unwin, Anne Barton
Development and validation of a methotrexate adherence assay. Annals of the rheumatic diseases 78 (9) (2019)

James Bluett.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

James Bluett